Evidence map›Paper›PMID 32184826›Full record

ArticleJournal of oncology2020

Antitumorigenic Effects of Inhibiting Ephrin Receptor Kinase Signaling by GLPG1790 against Colorectal Cancer Cell Lines

Alessandro Colapietro, Giovanni Luca Gravina, Francesco Petragnano, Irene Fasciani, Bianca Maria Scicchitano, Filip Beirinckx, Philippe Pujuguet, Laurent Saniere, Ellen Van der Aar, Daniela Musio and 7 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Optimization of the Lead Compound NVP-BHG712 as a Colorectal Cancer Inhibitor.Chemistry (Weinheim an der Bergstrasse, Germany) · 2023
    Article
  4. Article
  5. The Importance of Tumor Stem Cells in Glioblastoma Resistance to Therapy.International journal of molecular sciences · 2021
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 4 countries.

Alessandro ColapietroDepartment of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L'Aquila, L'Aquila, Italy.
Giovanni Luca GravinaDepartment of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L'Aquila, L'Aquila, Italy.
Francesco PetragnanoDepartment of Biotechnological and Applied Clinical Sciences, Laboratory of Pharmacology, University of L'Aquila, L'Aquila, Italy.
Irene FascianiDepartment of Biotechnological and Applied Clinical Sciences, Laboratory of Pharmacology, University of L'Aquila, L'Aquila, Italy.ORCID https://orcid.org/0000-0002-0345-082X
Bianca Maria ScicchitanoIstituto di Istologia ed Embriologia, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli, Largo Francesco Vito 1-00168, Roma, Italy.ORCID https://orcid.org/0000-0002-9599-6642
Filip BeirinckxGalapagos NV, Mechelen, Belgium.
Philippe PujuguetGalapagos SASU, Romainville, France.
Laurent SaniereGalapagos SASU, Romainville, France.
Ellen Van der AarGalapagos NV, Mechelen, Belgium.
Daniela MusioDepartment of Radiotherapy, Hospital Umberto I "Sapienza", University of Rome, Rome, Italy.
Francesca De FeliceDepartment of Radiotherapy, Hospital Umberto I "Sapienza", University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0002-5401-1595
Vincenzo MatteiLaboratory of Experimental Medicine and Enviromental Pathology, University Hub "Sabina Univeristas", Rieti, Italy.ORCID https://orcid.org/0000-0003-4677-088X
Stefano MartellucciDepartment of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L'Aquila, L'Aquila, Italy.ORCID https://orcid.org/0000-0002-3952-3162
Roberto MaggioDepartment of Biotechnological and Applied Clinical Sciences, Laboratory of Pharmacology, University of L'Aquila, L'Aquila, Italy.ORCID https://orcid.org/0000-0003-4436-2356
Vincenzo TomboliniDepartment of Radiotherapy, Hospital Umberto I "Sapienza", University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0001-5359-9991
Claudio FestucciaDepartment of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L'Aquila, L'Aquila, Italy.ORCID https://orcid.org/0000-0002-3463-6475
Francesco MaramponDepartment of Radiotherapy, Hospital Umberto I "Sapienza", University of Rome, Rome, Italy.
University of L'Aquila · ITPoliclinico Umberto I · ITGalapagos (Belgium) · BEGalapagos (France) · FRInstitute of Experimental Physics of the Slovak Academy of Sciences · SKUniversità Cattolica del Sacro Cuore · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Erythropoietin-producing hepatocellular receptors (Eph) promote the onset and sustain the progression of cancers such as colorectal cancer (CRC), in which the A2 subtype of Eph receptor expression has been shown to correlate with a poor prognosis and has been identified as a promising therapeutic target. Herein, we investigated,

Identifiers

PMID32184826
PMCPMC7063197
OpenAlexW3008365599

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.